1. Aabo K, Peedersen AG, Hald I, Dombernowky P (1982) High-dose medroxyprogesteron-acetate in advanced chemotherapy-resistant ovarian carcinoma: a phase II study. Cancer Treat Rep 66: 407
2. Alberti W, Bamberger M, Schulz U (1984) Granulosazelltumoren. Ergebnisse der postoperativen Bestrahlung. Dtsch Med Wochenschr 109: 750–752
3. Alberts D, Green S, Hannigan E et al. (1989) Improved efficacy of carboplatin/cyclophosphamide versus cisplatin/cyclophosphamide: preliminary report of a phase III, randomized trial in stages III-IV, suboptimal ovarian cancer. Proc Am Soc Clin Oncol 8: 151
4. Alberts DS, Liu PY, Hannigan EV et al. (1995) Phase III study of intraperitoneal cisplatin and intravenous cyclophosphamide vs intravenous cisplatin and intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study (Int 0051). Am Soc Clin Oncol, Abstr 760
5. Alberts DS, Liu PY, Hannigan EV et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955